The Week in Review: Innovation

The first SEED Life Sciences Business Plan Competition chose as its winner Dr. Yuqiang Wang from Guangzhou Jinan University College of Pharmacy; Sanofi-Aventis opened an R&D center in Shanghai which will manage partnerships with indigenous China biopharmas; Kun Run Biotech raised $8 million from OrbiMed; Artepharm China completed a reverse merger with Artepharm Global to market a malaria drug; NeoStem and a subsidiary of IR BioSciences announced a stem cell collaboration; Eisai licensed the China rights to a gastroprokinetic agent from Almirall of Spain; Lotus Pharma (路坦制药有限公司) expects SFDA approval to begin clinical trials of its asthma drug Laevo-Bambutero; Simcere Pharma (先声药业) said its diarrhea API passed EU-GMP inspection; and ATS Medical reported the first commercial use of its ATS 3f® Aortic Bioprosthesis in China. More details… Stock Symbols: (NYSE: SNY) (OTCBB: KURU) (OTCBB: ARGC) (NYSE Amex: NBS) (OTCBB: IRBS) (OTCBB: LTUS) (NYSE: SCR) (NSDQ: ATSI)